liver safety
BioAge Labs Halts Phase 2 Obesity Trial Due to Liver Safety Concerns Just Two Months After IPO
BioAge Labs, Phase 2 trial, obesity, liver safety concerns, azelaprag, Eli Lilly, tirzepatide, IPO
Actionable Insights Powered by AI
BioAge Labs, Phase 2 trial, obesity, liver safety concerns, azelaprag, Eli Lilly, tirzepatide, IPO